Intech Investment Management LLC boosted its position in shares of Alkermes plc (NASDAQ:ALKS - Free Report) by 30.4% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 68,151 shares of the company's stock after buying an additional 15,878 shares during the quarter. Intech Investment Management LLC's holdings in Alkermes were worth $1,960,000 at the end of the most recent quarter.
A number of other hedge funds have also recently bought and sold shares of the company. CIBC Asset Management Inc boosted its position in shares of Alkermes by 4.4% during the 4th quarter. CIBC Asset Management Inc now owns 9,155 shares of the company's stock valued at $263,000 after purchasing an additional 384 shares in the last quarter. KBC Group NV boosted its holdings in Alkermes by 18.8% during the third quarter. KBC Group NV now owns 4,890 shares of the company's stock worth $137,000 after buying an additional 774 shares in the last quarter. EverSource Wealth Advisors LLC boosted its holdings in Alkermes by 106.2% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,635 shares of the company's stock worth $47,000 after buying an additional 842 shares in the last quarter. Venturi Wealth Management LLC acquired a new position in Alkermes in the fourth quarter worth approximately $25,000. Finally, Exchange Traded Concepts LLC increased its holdings in shares of Alkermes by 3.0% in the fourth quarter. Exchange Traded Concepts LLC now owns 30,950 shares of the company's stock valued at $890,000 after buying an additional 897 shares in the last quarter. 95.21% of the stock is owned by institutional investors and hedge funds.
Alkermes Stock Down 2.6 %
Shares of Alkermes stock traded down $0.91 on Tuesday, hitting $33.88. 1,407,682 shares of the company traded hands, compared to its average volume of 1,695,442. Alkermes plc has a 12-month low of $22.90 and a 12-month high of $36.45. The company has a market cap of $5.51 billion, a PE ratio of 15.61, a PEG ratio of 2.20 and a beta of 0.62. The company has a 50-day moving average price of $33.10 and a 200 day moving average price of $30.12.
Alkermes (NASDAQ:ALKS - Get Free Report) last issued its earnings results on Wednesday, February 12th. The company reported $0.92 EPS for the quarter, beating analysts' consensus estimates of $0.81 by $0.11. Alkermes had a return on equity of 30.80% and a net margin of 23.57%. Equities research analysts anticipate that Alkermes plc will post 1.31 EPS for the current year.
Insider Buying and Selling
In other Alkermes news, EVP Craig C. Hopkinson sold 144,419 shares of the business's stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $35.53, for a total value of $5,131,207.07. Following the completion of the sale, the executive vice president now directly owns 57,875 shares of the company's stock, valued at $2,056,298.75. The trade was a 71.39 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 4.89% of the stock is currently owned by corporate insiders.
Wall Street Analysts Forecast Growth
ALKS has been the topic of a number of recent research reports. The Goldman Sachs Group lifted their target price on Alkermes from $30.00 to $32.00 and gave the stock a "buy" rating in a report on Friday, February 14th. Royal Bank of Canada initiated coverage on Alkermes in a report on Thursday, March 13th. They set a "sector perform" rating and a $40.00 price objective on the stock. UBS Group upgraded shares of Alkermes from a "sell" rating to a "neutral" rating and raised their target price for the stock from $21.00 to $38.00 in a report on Tuesday, March 4th. Deutsche Bank Aktiengesellschaft began coverage on shares of Alkermes in a research report on Tuesday, February 11th. They issued a "buy" rating and a $40.00 target price on the stock. Finally, HC Wainwright restated a "neutral" rating and issued a $46.00 price target on shares of Alkermes in a research report on Thursday, February 13th. Four research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $38.46.
Check Out Our Latest Report on ALKS
About Alkermes
(
Free Report)
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.
Featured Articles
Before you consider Alkermes, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alkermes wasn't on the list.
While Alkermes currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
